Rallybio Corporation (NASDAQ:RLYB) Sees Large Growth in Short Interest

Rallybio Corporation (NASDAQ:RLYB) was the target of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 141,643 shares, an increase of 21.5% from the January 15th total of 116,605 shares. Based on an average daily volume of 169,162 shares, the days-to-cover ratio is currently 0.8 days. Currently, 3.0% of the shares of the stock are sold short. Currently, 3.0% of the shares of the stock are sold short. Based on an average daily volume of 169,162 shares, the days-to-cover ratio is currently 0.8 days.

Hedge Funds Weigh In On Rallybio

Institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd increased its stake in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after purchasing an additional 38,205 shares during the period. Susquehanna International Group LLP grew its holdings in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the period. Citadel Advisors LLC raised its holdings in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares during the period. 90.34% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $40.00.

Rallybio Stock Performance

RLYB stock opened at $4.45 on Thursday. The firm has a market cap of $23.50 million, a P/E ratio of -1.74 and a beta of -1.05. The firm’s fifty day moving average is $5.39 and its 200 day moving average is $4.99. Rallybio has a 52 week low of $1.76 and a 52 week high of $6.75.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.